Journal of ethnopharmacology · 2026
The material basis and underlying mechanism of Folium Artemisiae Argyi in warming meridians and alleviating pain in a rat model of cold-dampness stagnation primary dysmenorrhea.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Wei Miaomiao, Zhang Mei, Qi Ruihua, Du Lei, Li Min, Yang Junxuan, Zhao Qianqian, Chen Huali, Ke Xiumei
Аннотация
ETHNOPHARMACOLOGICAL RELEVANCE: Dysmenorrhea significantly impairs quality of life in women. Folium Artemisiae Argyi (FAA), known for its ability to warm meridians, arrest bleeding, disperse cold, and alleviate pain, is commonly used to treat gynecological conditions, including lower abdominal cold pain and irregular menstruation, though its material basis and mechanism remain unclear.
AIM: To elucidate the material basis and mechanism underlying the meridian-warming and pain-alleviating effects of FAA in a rat model of cold-damp stagnation-type primary dysmenorrhea (CDST-PD).
METHODS: We established a CDST-PD rat model using combined estradiol benzoate and ice-water stimulation. The therapeutic efficacy of FAA was assessed through oxytocin-induced writhing responses and histopathological examination, alongside measurements of estradiol (E2), progesterone (Prog), thromboxane B2 (TXB2), interleukin-6 (IL-6), and tumor necrosis factor-α (TNF-α). Ultra-high performance liquid chromatography quadrupole-time-of-flight mass spectrometry (UPLC-Q-TOF/MS) characterized the components of Artemisia argyi decoction (AAD). Network pharmacology predicted potential material basis and core therapeutic targets, with molecular docking validating the binding interactions between key components and targets. Quantitative real-time polymerase chain reaction (RT-qPCR) was then used to quantify mRNA expression of relevant genes in uterine tissue to investigate the mechanism underlying FAA's meridian-warming and pain-alleviating effects.
RESULTS: FAA alleviated CDST-PD by improving uterine and ovarian histopathology, reducing E2 and TXB2 levels, increasing Prog concentration, and inhibiting IL-6 and TNF-α expression. UPLC-Q-TOF/MS and network pharmacology revealed 5 key compounds, including eupatilin and vitexicarpin, that targeted proteins such as IL6, AKT1, and TNF. Molecular docking confirmed strong binding potential, while RT-qPCR demonstrated that FAA downregulated mRNA expression of HIF1A, PI3K, mTOR, AKT, NFKB1, and ERK1, suggesting that the PI3K/AKT-NFKB1/ERK1/mTOR-HIF1A and PI3K/AKT-NFKB1/ERK1-inflammatory factors pathways mediated its therapeutic effects.
CONCLUSIONS: This study investigated the material basis and mechanisms of FAA's "warming meridians and alleviating pain" effects in a CDST-PD rat model. FAA primarily acts through compounds such as eupatilin and vitexicarpin, which modulate the PI3K/AKT-NFΚB1/ERK1/mTOR-HIF1A and PI3K/AKT-NFΚB1/ERK1-inflammatory factors pathways to regulate E2, TXB2, Prog, IL-6, and TNF-α levels. These findings provide a modern pharmacological basis for FAA's traditional application.
AIM: To elucidate the material basis and mechanism underlying the meridian-warming and pain-alleviating effects of FAA in a rat model of cold-damp stagnation-type primary dysmenorrhea (CDST-PD).
METHODS: We established a CDST-PD rat model using combined estradiol benzoate and ice-water stimulation. The therapeutic efficacy of FAA was assessed through oxytocin-induced writhing responses and histopathological examination, alongside measurements of estradiol (E2), progesterone (Prog), thromboxane B2 (TXB2), interleukin-6 (IL-6), and tumor necrosis factor-α (TNF-α). Ultra-high performance liquid chromatography quadrupole-time-of-flight mass spectrometry (UPLC-Q-TOF/MS) characterized the components of Artemisia argyi decoction (AAD). Network pharmacology predicted potential material basis and core therapeutic targets, with molecular docking validating the binding interactions between key components and targets. Quantitative real-time polymerase chain reaction (RT-qPCR) was then used to quantify mRNA expression of relevant genes in uterine tissue to investigate the mechanism underlying FAA's meridian-warming and pain-alleviating effects.
RESULTS: FAA alleviated CDST-PD by improving uterine and ovarian histopathology, reducing E2 and TXB2 levels, increasing Prog concentration, and inhibiting IL-6 and TNF-α expression. UPLC-Q-TOF/MS and network pharmacology revealed 5 key compounds, including eupatilin and vitexicarpin, that targeted proteins such as IL6, AKT1, and TNF. Molecular docking confirmed strong binding potential, while RT-qPCR demonstrated that FAA downregulated mRNA expression of HIF1A, PI3K, mTOR, AKT, NFKB1, and ERK1, suggesting that the PI3K/AKT-NFKB1/ERK1/mTOR-HIF1A and PI3K/AKT-NFKB1/ERK1-inflammatory factors pathways mediated its therapeutic effects.
CONCLUSIONS: This study investigated the material basis and mechanisms of FAA's "warming meridians and alleviating pain" effects in a CDST-PD rat model. FAA primarily acts through compounds such as eupatilin and vitexicarpin, which modulate the PI3K/AKT-NFΚB1/ERK1/mTOR-HIF1A and PI3K/AKT-NFΚB1/ERK1-inflammatory factors pathways to regulate E2, TXB2, Prog, IL-6, and TNF-α levels. These findings provide a modern pharmacological basis for FAA's traditional application.